Organovo Holdings, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Keith E. Murphy
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11555 Sorrento Valley Road Solana Beach CA United States of America 92121
- IPO Date
- Feb 14, 2012
- CIK
- 0001497253
- Website
- organovo.com
- Similar Companies
- Business
- Organovo Holdings, Inc. (Nasdaq: ONVO) develops three-dimensional human tissues that recapitulate key aspects of human biology and disease for applications in drug discovery, preclinical testing, and therapeutic development; its proprietary NovoGen Bioprinters enable the fabrication of complex multicellular tissues using bio-inks composed of mammalian cells; core products include ExVive human liver tissues and ExVive human kidney tissues for predictive toxicology, drug metabolism, absorption, distribution, metabolism, excretion (ADME), and pharmacokinetics (DMPK) assessments, alongside custom tissue services, Mosaic Cell Sciences division for primary human cells, and historical offerings in disease modeling for inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, and metabolic dysfunction-associated steatohepatitis (MASH). The company, founded in 2007 and headquartered in Solana Beach, California, operates primarily in the United States with a focus on pharmaceutical and academic research customers. In recent developments, Organovo completed the sale of its FXR program, including lead asset FXR314 for IBD treatments, to Eli Lilly and Company in March 2025 for an undisclosed upfront payment plus up to $50 million in milestones; announced on April 23, 2025, that VivoSim Labs, Inc. will carry forward its 3D bioprinting technology and legacy assets; effected a 1-for-12 reverse stock split effective March 20, 2025, to regain Nasdaq compliance; appointed Norman Staskey as Chief Financial Officer in January 2025; issued additional shares from warrant exercises raising approximately $2.3 million gross proceeds in March 2025; reported preliminary fiscal year-end cash of $11.3 million as of March 31, 2025, with quarterly cash burn of $2.0-$2.2 million and expectations for a $5 million milestone within 12 months; and anticipates full Q2 fiscal 2026 results in June 2025.
Will the ONVO L90's Fast Market Entry Boost NIO's Competitive Edge?
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
VivoSim to Carry Forward Organovo 3D Bioprinting
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
Organovo Provides Business Update
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
Organovo Announces Reverse Stock Split
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Nio stock poised for 42% gain on ONVO sales momentum
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Organovo's fatty liver disease drug meets main goal in mid-stage study
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo